Linkage

Linkage Therapeutics is a biotechnology company focused on developing a novel class of therapeutics known as intrabodies to treat neurodegenerative diseases. Utilizing its proprietary PTAP™ (Programmable Target Antigen Proteolysis) platform, the company engineers bifunctional antibody fragments that operate inside cells to selectively degrade toxic, disease-causing proteins while sparing their healthy counterparts. The company's pipeline includes programs targeting mutant huntingtin for Huntington's disease, tau for Alzheimer's disease, and alpha-synuclein for Parkinson's disease. Linkage Therapeutics aims to transform the treatment of proteinopathies by clearing pathogenic aggregates at their source.